Dr. Concepcion on the Use of Eligard in Prostate Cancer Treatment

Video

Raoul Concepcion, MD, director, Comprehensive Prostate Center, discusses the use of Eligard in the treatment of prostate cancer with OncLive during the LUGPA Annual Meeting.

Raoul Concepcion, MD, director, Comprehensive Prostate Center, discusses the use of Eligard in the treatment of prostate cancer with OncLive during the LUGPA Annual Meeting.

Eligard, manufactured by Tolmar, is an LHRH agonist which overdrives the testical for a brief period of time, resulting in a castration level of testosterone.

What makes Eligard unique is its delivery system, Concepcion says. Eligard's Atrigel delivery system is a slow release, which results in lower, sustained levels of testosterone.

Related Videos
Kara N. Maxwell, MD, PhD
Ruben Olivares, MD
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Jeffrey P. Townsend, PhD
Rohan Garje, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Carmen Guerra, MD, MSCE, FACP
Kara N. Maxwell, MD, PhD
Josep Maria Piulats Rodriguez, MD, PhD
Phillip J. Koo, MD